Sight Sciences Q4 revenue $20.4M (+7% YoY); guides 2026 revenue $82-88M

Sight Sciences, Inc.

Q4 2025 revenue $20.4M (+7% YoY); Interventional Glaucoma $19.7M (+5% YoY); Dry Eye $0.7M vs $0.3M.
Q4 net loss $4.2M ($0.08 loss per share) vs $11.8M loss in Q4 2024; full-year net loss $38.4M vs $51.5M.
Cash $92M at Dec 31, 2025; Q4 cash used only $0.4M; full-year cash used $28.4M.
FY 2026 guidance: revenue $82-88M (+6-14% YoY); Glaucoma $77-81M; Dry Eye $5-7M.
Operating expenses down 25% Q4 and 13% full-year; adjusted op ex guidance $93-96M for 2026.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Sight Sciences, Inc. reported the fourth quarter and full year ended December 31, 2025 results: revenue $20.4 million, net income $4.2 million, EPS $0.08 per share. Guidance initiated.

Period: the fourth quarter and full year ended December 31, 2025
Revenue: $20.4 million
Net income: $4.2 million
EPS: $0.08 per share
Guidance: initiated
Result: reported results

Exact text from the filing

quarter and full year ended December 31, 2025 and initiated financial guidance for full year 2026. Recent Financial Highlights • Generated fourth quarter 2025 total revenue of $20.4 million, an increase of 7% compared to the same period in the prior year, and full year 2025 total revenue of $77.4 million, a decrease of 3% compared to full year 2024. • Achieved total

View on SEC.gov

44 earnings releases filed in the last 30 days. Browse all earnings releases →

Sight Sciences, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-091482

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.